TGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TG Therapeutics (TGTX) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some supportive factors—bullish moving averages, a favorable analyst target increase, and positive options sentiment—but the current momentum is mixed, there is no fresh news catalyst, and proprietary trading signals are absent. Because the user is unwilling to wait for an optimal entry, this still does not present a clean, high-confidence buy at the current price of 39.12. The better call is to hold and wait for either a clearer breakout above resistance or a stronger catalyst.
Current trend is mixed but constructive. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports the longer-term uptrend. However, MACD histogram is -0.384 and negatively expanding, showing short-term momentum is weakening. RSI_6 at 41.426 is neutral-to-soft, not oversold enough to suggest a strong immediate bounce. Price at 39.12 is sitting just above S1 support at 38.706 and below pivot 40.922, which places it in a slightly vulnerable mid-range rather than a strong breakout zone. Near-term pattern data suggests small upside tomorrow and over the next month, but a weak next-week expectation.
["H.C. Wainwright raised the price target to $70 from $60 and kept a Buy rating after Q1 earnings.", "The firm cited higher U.S. Briumvi and total revenue estimates, improving confidence in 2026 performance.", "Bullish moving average structure suggests the longer-term trend remains intact.", "Options positioning is call-heavy, reflecting constructive trader sentiment."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "MACD is negative and weakening, signaling short-term momentum deterioration.", "RSI is only neutral, not showing strong bullish urgency.", "Hedge funds and insiders are both neutral with no significant recent activity.", "No recent congress trading data available.", "No AI Stock Picker signal and no SwingMax signal today."]
Latest quarter financials were not available because the financial snapshot returned an error, so I cannot confirm revenue, earnings, or margin trends from the provided data. The only available fundamental clue is the analyst commentary referencing Q1 earnings, which implies the company reported enough strength to justify upward target revisions and higher revenue estimates.
Recent analyst trend is positive. On 2026-05-06, H.C. Wainwright raised its target to $70 from $60 and reiterated Buy, pointing to greater confidence in 2026 performance after Q1 earnings. Wall Street pros appear constructive on growth and revenue trajectory, but the broader picture from the provided data is limited since only one rating update is shown. Overall, the analyst view is bullish, though not strongly validated by broader insider, hedge fund, or news support.
